RARECELLS

DETECT AND DEFEAT CANCER FROM ITS START

THROUGH A SIMPLE BLOOD DRAW

ISET® PLATFORM

VERSATILITY, SENSITIVITY

INTACT LABEL-FREE FIXED AND LIVING CELLS FROM A BLOOD DRAW

APPLICATIONS

FOSTER YOUR RESEARCH STUDIES

ACCESSING THE RIGHT CIRCULATING TUMOR CELLS & CTC DNA

RARECELLS

OUTSMARTING CANCER

FROM ONSET TO REMISSION

ISET® PLATFORM

VERSATILITY, SENSITIVITY

INTACT LABEL-FREE FIXED AND LIVING CELLS FROM A BLOOD DRAW

FOSTER YOUR RESEARCH STUDIES

ACCESSING THE RIGHT CIRCULATING TUMOR CELLS & CTC DNA

RARECELLS

DETECT AND DEFEAT CANCER FROM ITS START

THROUGH A SIMPLE BLOOD DRAW

ISET® PLATFORM

VERSATILITY, SENSITIVITY

INTACT LABEL-FREE FIXED AND LIVING CELLS FROM A BLOOD DRAW

BOOST YOUR RESEARCH STUDIES

ACCESSING THE RIGHT CIRCULATING TUMOR CELLS & CTC DNA

RARECELLS

FROM RESEARCH TO CLINIC

From a 10mL blood draw, ISET® system is capturing intact CTC ready for downstream analysis from cytology to DNA analysis.

ISET® isolated CTC, a reliable source to foster research applied to early detection, prognosis, and theranostic

Learn more about the ISET® cytology blood test

ANY QUESTIONS? NEED FOR INFORMATION?

LEARN ABOUT

ISET TECHNOLOGY AND CTC

NEWS

Vanity Fair Italy Interviews Rarecells Founder Dr. Patrizia Paterlini

June 30, 2025

Rarecells, Inc. Appoints Dr. Rita Shaknovich to Scientific Advisory Board

June 18, 2025

Press Release: Rarecells, Inc. Appoints Dr. Neil Kurtz to Board of Directors

March 26, 2025

Rarecells, Inc. USA

Rarecells Diagnostics
Paris, France